Literature DB >> 25941596

Lymphocyte activation gene-3 (LAG-3, CD223) in plasmacytoid dendritic cells (pDCs): a molecular target for the restoration of active antitumor immunity.

Chiara Castelli1, Frédéric Triebel2, Licia Rivoltini1, Chiara Camisaschi1.   

Abstract

We have recently reported that lymphocyte activation gene-3 (LAG-3,CD223) mediates the alternative, IFNα-deficient activation of plasmacytoid dendritic cells (pDCs) at tumor sites. Our findings define a novel tumor-driven strategy that promotes immunosuppression by pDCs, and we have provided more detailed information regarding the immunomodulatory role of of LAG-3. The translational relevance of our results for the treatment of tumors and autoimmune diseases is discussed herein.

Entities:  

Keywords:  ADCC, antibody-dependent cell cytotoxicity; APCs, antigen-presenting cells; DDCs, dermal dendritic cells; IMP-321; LAG-3, lymphocyte activation gene-3; LNs, lymph nodes; MDSCs, myeloid-derived suppressor cells; PD-1, programmed cell death 1; TLRs, toll-like receptors; Tregs, regulatory T cells.; lymphocyte activation gene-3 (LAG-3); mAbs, monoclonal antibodies; melanoma; pDCs, plasmacytoid dendritic cells; plasmacytoid dendritic cells (pDCs); psoriasis

Year:  2014        PMID： 25941596      PMCID： PMC4292561          DOI： 10.4161/21624011.2014.967146

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma.

Authors:  Trine O Jensen; Henrik Schmidt; Holger J Møller; Frede Donskov; Morten Høyer; Pia Sjoegren; Ib J Christensen; Torben Steiniche
Journal:  Cancer       Date:  2011-09-22       Impact factor: 6.860

2.  Anticancer TLR agonists on the ropes.

Authors:  Malini Guha
Journal:  Nat Rev Drug Discov       Date:  2012-06-29       Impact factor: 84.694

3.  Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion.

Authors:  Jurjen Tel; Simone P Sittig; Rebecca A M Blom; Luis J Cruz; Gerty Schreibelt; Carl G Figdor; I Jolanda M de Vries
Journal:  J Immunol       Date:  2013-10-14       Impact factor: 5.422

4.  Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Authors:  Junko Matsuzaki; Sacha Gnjatic; Paulette Mhawech-Fauceglia; Amy Beck; Austin Miller; Takemasa Tsuji; Cheryl Eppolito; Feng Qian; Shashikant Lele; Protul Shrikant; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

5.  Alternative activation of human plasmacytoid DCs in vitro and in melanoma lesions: involvement of LAG-3.

Authors:  Chiara Camisaschi; Annamaria De Filippo; Valeria Beretta; Barbara Vergani; Antonello Villa; Elisabetta Vergani; Mario Santinami; Antonello Domenico Cabras; Flavio Arienti; Frédéric Triebel; Monica Rodolfo; Licia Rivoltini; Chiara Castelli
Journal:  J Invest Dermatol       Date:  2014-01-17       Impact factor: 8.551

6.  The pathogenic role of tissue-resident immune cells in psoriasis.

Authors:  Onur Boyman; Curdin Conrad; Giulia Tonel; Michel Gilliet; Frank O Nestle
Journal:  Trends Immunol       Date:  2007-01-02       Impact factor: 16.687

7.  LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites.

Authors:  Chiara Camisaschi; Chiara Casati; Francesca Rini; Michela Perego; Annamaria De Filippo; Frédéric Triebel; Giorgio Parmiani; Filiberto Belli; Licia Rivoltini; Chiara Castelli
Journal:  J Immunol       Date:  2010-04-26       Impact factor: 5.422

8.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.

Authors:  Nicola Gagliani; Chiara F Magnani; Samuel Huber; Monica E Gianolini; Mauro Pala; Paula Licona-Limon; Binggege Guo; De'Broski R Herbert; Alessandro Bulfone; Filippo Trentini; Clelia Di Serio; Rosa Bacchetta; Marco Andreani; Leonie Brockmann; Silvia Gregori; Richard A Flavell; Maria-Grazia Roncarolo
Journal:  Nat Med       Date:  2013-04-28       Impact factor: 53.440

Review 9.  Plasmacytoid dendritic cells: recent progress and open questions.

Authors:  Boris Reizis; Anna Bunin; Hiyaa S Ghosh; Kanako L Lewis; Vanja Sisirak
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

10.  Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.

Authors:  Chiara Casati; Chiara Camisaschi; Francesca Rini; Flavio Arienti; Licia Rivoltini; Frédéric Triebel; Giorgio Parmiani; Chiara Castelli
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701
  10 in total
  9 in total

1.  Resident plasmacytoid dendritic cells patrol vessels in the naïve limbus and conjunctiva.

Authors:  Arsia Jamali; Deshea L Harris; Tomas Blanco; Maria J Lopez; Pedram Hamrah
Journal:  Ocul Surf       Date:  2020-02-25       Impact factor: 5.033

Review 2.  Immunosuppressive cells in tumor immune escape and metastasis.

Authors:  Yang Liu; Xuetao Cao
Journal:  J Mol Med (Berl)       Date:  2015-12-22       Impact factor: 4.599

3.  LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.

Authors:  Wei-Wei Deng; Liang Mao; Guang-Tao Yu; Lin-Lin Bu; Si-Rui Ma; Bing Liu; J Silvio Gutkind; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2016-10-07       Impact factor: 8.110

4.  Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.

Authors:  Cinzia Solinas; Soizic Garaud; Pushpamali De Silva; Anaïs Boisson; Gert Van den Eynden; Alexandre de Wind; Paolo Risso; Joel Rodrigues Vitória; François Richard; Edoardo Migliori; Grégory Noël; Hugues Duvillier; Ligia Craciun; Isabelle Veys; Ahmad Awada; Vincent Detours; Denis Larsimont; Martine Piccart-Gebhart; Karen Willard-Gallo
Journal:  Front Immunol       Date:  2017-10-30       Impact factor: 7.561

5.  Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.

Authors:  Felix S Lichtenegger; Maurine Rothe; Frauke M Schnorfeil; Katrin Deiser; Christina Krupka; Christian Augsberger; Miriam Schlüter; Julia Neitz; Marion Subklewe
Journal:  Front Immunol       Date:  2018-02-27       Impact factor: 7.561

Review 6.  Disease-Associated Plasmacytoid Dendritic Cells.

Authors:  Shuang Li; Jing Wu; Shan Zhu; Yong-Jun Liu; Jingtao Chen
Journal:  Front Immunol       Date:  2017-10-16       Impact factor: 7.561

Review 7.  The Role of Plasmacytoid Dendritic Cells in Gut Health.

Authors:  Hye-Yeon Won; Ju-Young Lee; Dahye Ryu; Hyung-Taek Kim; Sun-Young Chang
Journal:  Immune Netw       Date:  2019-01-16       Impact factor: 6.303

Review 8.  The Role of Plasmacytoid Dendritic Cells in Cancers.

Authors:  Binhui Zhou; Toby Lawrence; Yinming Liang
Journal:  Front Immunol       Date:  2021-10-19       Impact factor: 7.561

9.  Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation.

Authors:  Linda Kocovski; Anita Bane; Shangguo Tang; Samih Salama; Salem Alowami
Journal:  Rare Tumors       Date:  2015-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.